Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: New Investigator Award - PA: HIV/AIDS Services/Population Health Research

McGill University

$300,000.00

Multiplex screening assays for HIV and co-infections: will they benefit patients, providers and health care systems?

EF 2009-10

Résumé
Targeted screening of at risk individuals is a proven cost effective strategy. Vulnerable at risk populations are difficult to follow up, so that regular screening for all co-infections and HIV is often not conducted in them. Due to the asymptomatic nature of early infections and the lack of consistent screening, a vast majority of affected individuals are living with un-diagnosed infection. Early diagnosis and early treatment are proven to reduce morbidity and mortality, health care costs and transmission. Recently developed multiplex strategy makes it possible to inexpensively test individuals multiple infections with just a single drop of blood, with immediate results precluding the need for follow-up visits. Multiplo(TM) (MedMira Inc, Halifax, Canada), is one such multiplex point-of-care device that detects four infections (i.e., HIV, HBV, HCV and Syphilis) with a small 5 micro-litre finger stick blood sample in 5 minutes. In this proposal, we will investigate whether introducing Multiplo(TM) as a first line screening assay helps impact: a) detection of new infections and expedite initiation of treatment in patients; b) facilitate clinical decision making by health care providers; c) improves estimates of co-prevalence; and, d) lastly, offer cost and time savings to the health care systems.
Programme
New Investigator Award - PA: HIV/AIDS Services/Population Health Research
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
192508
Name
Pai Nitika
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Population and Public Health
Theme2
Clinical
Prcname2
Health Research Salary A
Projecttitle
Multiplex screening assays for HIV and co-infections: will they benefit patients, providers and health care systems?
Programtype2
Salary Programs
Orgnameinp2
McGill University
Cihramount2
$300,000
Cihrequipment2
$0
Programname2
New Investigator Award - PA: HIV/AIDS Services/Population Health Research
Keyworddelim
Co-Infections; Hiv; Impact; Multiplex Assays; Screening Strategy; Vulnerable
Abstract
Targeted screening of at risk individuals is a proven cost effective strategy. Vulnerable at risk populations are difficult to follow up, so that regular screening for all co-infections and HIV is often not conducted in them. Due to the asymptomatic nature of early infections and the lack of consistent screening, a vast majority of affected individuals are living with un-diagnosed infection. Early diagnosis and early treatment are proven to reduce morbidity and mortality, health care costs and transmission. Recently developed multiplex strategy makes it possible to inexpensively test individuals multiple infections with just a single drop of blood, with immediate results precluding the need for follow-up visits. Multiplo(TM) (MedMira Inc, Halifax, Canada), is one such multiplex point-of-care device that detects four infections (i.e., HIV, HBV, HCV and Syphilis) with a small 5 micro-litre finger stick blood sample in 5 minutes. In this proposal, we will investigate whether introducing Multiplo(TM) as a first line screening assay helps impact: a) detection of new infections and expedite initiation of treatment in patients; b) facilitate clinical decision making by health care providers; c) improves estimates of co-prevalence; and, d) lastly, offer cost and time savings to the health care systems.
Competitiondate
200909
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Pai, Nitika
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $300,000~ $0~